Merck KGaA Profit Beats Estimates on Cost-Cutting
May 14 (Bloomberg) -- Merck KGaA, the German maker of cancer drug Erbitux, said first-quarter profit rose on higher-than-expected savings from a reorganization program, and forecast it will achieve 2014 targets a year ahead of schedule. Mark Barton reports on Bloomberg Television's "Countdown." (Source: Bloomberg)
Most Recent Videos
The Challenges Facing Central Banks
52:24 - Columbia Threadneedle EMEA CIO and Global Head of Equities Mark Burgess discusses the outlook for the Fed and the ECB with Mark Barton on "Bloomberg Surveillance."